Senescent cells (SNCs) are a key factor in aging and age-related diseases. They are non-dividing cells that accumulate over time and contribute to conditions such as cancer, atherosclerosis, and osteoarthritis by secreting harmful factors. Therapeutic strategies to eliminate SNCs or block their secretome are being explored as potential treatments for aging-related diseases. These strategies include senolysis, which removes SNCs, and SASP neutralization, which blocks the harmful effects of SNC secretions. Senolysis has shown promise in animal models, extending healthspan and lifespan, and reducing disease progression. However, challenges remain, including the need to target SNCs safely and effectively, avoid off-target effects, and ensure long-term safety. Current senolytic agents, such as navitoclax and UBX0101, have shown potential in preclinical studies. Additionally, immune-mediated clearance of SNCs is being investigated, as well as the use of SASP neutralizing agents. Despite these advances, further research is needed to translate these findings into effective therapies for aging-related diseases.Senescent cells (SNCs) are a key factor in aging and age-related diseases. They are non-dividing cells that accumulate over time and contribute to conditions such as cancer, atherosclerosis, and osteoarthritis by secreting harmful factors. Therapeutic strategies to eliminate SNCs or block their secretome are being explored as potential treatments for aging-related diseases. These strategies include senolysis, which removes SNCs, and SASP neutralization, which blocks the harmful effects of SNC secretions. Senolysis has shown promise in animal models, extending healthspan and lifespan, and reducing disease progression. However, challenges remain, including the need to target SNCs safely and effectively, avoid off-target effects, and ensure long-term safety. Current senolytic agents, such as navitoclax and UBX0101, have shown potential in preclinical studies. Additionally, immune-mediated clearance of SNCs is being investigated, as well as the use of SASP neutralizing agents. Despite these advances, further research is needed to translate these findings into effective therapies for aging-related diseases.